Catheter Precision (VTAK)
XASE:VTAK
Want to see VTAK full AI Analyst Report?
Top Page
Catheter Precision
(NYSE MKT:VTAK)
Select Model
Select Model
Rating:45Neutral
Price Target:
$1.00
▼(-44.75% Downside)
Action:Reiterated
Date:06/09/26
The score is primarily held down by very weak financial performance—tiny revenue base relative to extreme losses and sustained cash burn—implying ongoing dependence on external capital. Technicals are mixed with some short-term strength but a longer-term downtrend and stretched momentum signals. Valuation is constrained by negative earnings, while recent financing and strategic investment modestly support the outlook but add dilution and execution risk.
Positive Factors
Proprietary EP mapping catheter
Owning a proprietary electrophysiology mapping catheter gives the company a focused product moat in arrhythmia procedures. Durable per‑procedure demand for disposables and clinical integration can drive recurring revenue and create switching costs as adoption and physician familiarity grow over months to years.
Negative Factors
Sustained negative cash flow
Persistent multi‑million dollar operating and free cash flow deficits mean the business cannot self‑fund growth. Continued negative cash generation forces reliance on external financing, increasing dilution risk and creating execution risk if capital access tightens over the coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary EP mapping catheter
Owning a proprietary electrophysiology mapping catheter gives the company a focused product moat in arrhythmia procedures. Durable per‑procedure demand for disposables and clinical integration can drive recurring revenue and create switching costs as adoption and physician familiarity grow over months to years.
Read all positive factors
Catheter Precision (VTAK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.83M
Dividend YieldN/A
Average Volume (3M)309.34K
Price to Earnings (P/E)―
Beta (1Y)1.20
Revenue Growth130.35%
EPS Growth92.24%
CountryUS
Employees22
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-6.79
Shares Outstanding2,692,473
10 Day Avg. Volume759,143
30 Day Avg. Volume309,336
Financial Highlights & Ratios
PEG Ratio-0.83
Price to Book (P/B)280.34
Price to Sales (P/S)2414.57
P/FCF Ratio-237.88
Enterprise Value/Market Cap4.42
Enterprise Value/Revenue11.29
Enterprise Value/Gross Profit12.33
Enterprise Value/Ebitda-0.85
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-60.8
Revenue Forecast (FY)$10.20M
Catheter Precision Business Overview & Revenue Model
Company Description
Catheter Precision, Inc., headquartered in Fort Mill, South Carolina, is dedicated to creating and distributing electrophysiology products. Their mission is to enhance treatment and outcomes for U.S. patients suffering from cardiac arrhythmias by ...
How the Company Makes Money
Catheter Precision makes money primarily by selling its electrophysiology mapping catheters and related disposables used in hospital catheterization/electrophysiology labs during arrhythmia procedures. Revenue is generated on a per-procedure basis...
Catheter Precision Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
35
Negative
Cash Flow
10
Very Negative
| Breakdown | Mar 2026 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 819.00K | 420.00K | 442.00K | 14.00K | 22.00K |
| Gross Profit | 756.00K | 378.00K | 412.00K | -147.00K | -1.54M |
| EBITDA | -17.11M | -11.30M | -15.11M | -22.37M | -25.85M |
| Net Income | -17.18M | -16.64M | -70.57M | -26.86M | -25.07M |
Balance Sheet | |||||
| Total Assets | 15.86M | 27.77M | 30.74M | 16.84M | 21.04M |
| Cash, Cash Equivalents and Short-Term Investments | 88.00K | 2.87M | 3.56M | 15.86M | 15.04M |
| Total Debt | 3.85M | 1.79M | 372.00K | 0.00 | 2.26M |
| Total Liabilities | 9.21M | 16.01M | 9.54M | 7.58M | 7.37M |
| Stockholders Equity | 7.05M | 11.76M | 21.19M | 9.26M | 13.67M |
Cash Flow | |||||
| Free Cash Flow | -8.31M | -9.34M | -20.70M | -22.59M | -27.89M |
| Operating Cash Flow | -8.30M | -9.27M | -20.62M | -22.57M | -27.63M |
| Investing Cash Flow | 167.00K | -67.00K | -61.00K | 21.00K | 3.80M |
| Financing Cash Flow | 5.34M | 8.65M | 8.39M | 23.36M | 14.96M |
Catheter Precision Technical Analysis
Positive
1.81
Price Trends
0.94
Positive
1.26
Negative
1.78
Negative
Market Momentum
0.04
Negative
59.79
Neutral
63.07
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VTAK, the sentiment is Positive. The current price of 1.81 is above the 20-day moving average (MA) of 0.94, above the 50-day MA of 0.94, and above the 200-day MA of 1.78, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 59.79 is Neutral, neither overbought nor oversold. The STOCH value of 63.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VTAK.
Catheter Precision Risk Analysis
Catheter Precision disclosed 40 risk factors in its most recent earnings report. Catheter Precision reported the most risks in the "Production" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Issued shares of our convertible preferred stock are convertible into a substantial number of shares of common stock that, upon conversion, will significantly dilute our existing common stockholders. Q1, 2026
2.
We may issue additional series of convertible preferred stock under the Series C Purchase Agreements that, upon issuance and conversion, could result in extraordinary additional dilution to our existing common stockholders. Q1, 2026
3.
The market for short-range flights is still in relatively early stages of development, and the UAM, RAM and AAM markets may not develop as anticipated. Q1, 2026
Catheter Precision Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $2.83M | -155.21 | -173.74% | ― | 130.35% | 92.24% | |
45 Neutral | $35.80M | -0.41 | -9999.00% | ― | -95.74% | -118.94% | |
44 Neutral | $4.79M | -0.44 | -191.39% | ― | ― | 81.30% | |
43 Neutral | $1.82M | -0.01 | -6046.59% | ― | -0.20% | 91.63% | |
40 Underperform | $5.73M | -0.69 | -220.42% | ― | ― | 51.71% |
* Healthcare Sector Average
VTAK
Catheter Precision
1.05
-5.51
-83.99%
NUWE
Nuwellis
0.14
-11.62
-98.84%
AEMD
Aethlon Medical
2.00
-16.00
-88.89%
PAVM
PAVmed
4.83
-13.93
-74.25%
HSCS
Heart Test Laboratories, Inc.
1.84
-2.02
-52.33%
Catheter Precision Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Catheter Precision Makes Strategic Investment in Volato Group
Positive
Jun 8, 2026
On June 7, 2026, Catheter Precision, Inc. agreed to participate in a private placement by purchasing 2,941,176 shares of Volato Group, Inc. common stock at $0.34 per share, for a total of $1 million, a stake whose market value was approximately eq...
M&A TransactionsPrivate Placements and Financing
Catheter Precision Raises Capital Through New Preferred Stock
Positive
Apr 23, 2026
On April 21, 2026, Catheter Precision closed the sale of 3,470 shares of its newly created Series C-2 Convertible Preferred Stock at $1,000 per share, raising gross proceeds of $3.47 million to be used for working capital and general corporate nee...
Business Operations and StrategyShareholder MeetingsStock Split
Catheter Precision Shareholders Approve Reverse Split, Capital Changes
Neutral
Apr 15, 2026
On April 15, 2026, Catheter Precision held a Special Meeting of stockholders where approximately 49.5% of outstanding common shares were represented. Shareholders approved the issuance of common shares underlying the company’s Series C-1, C-...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.